Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial) - Moliterno, D J; Califf, R M; Aguirre, F V; Anderson, K; Sigmon, K N; Weisman, H F; Topol, E J (Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial, 1995)